Basic Information | Post buying leads | Suppliers | Cas Database |
Levosulpiride, its cas register number is 23672-07-3. It also can be called (S)-(-)-Sulpiride; (S)-5-Aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide; (-)-N-(((S)-1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide; Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-, (S)- (9CI); o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-, (S)-(-)- . It is an antipsychotic. Levosulpiride is used in the treatment of psychoses, particularly negative symptoms of schizophrenia, anxiety disorders, dysthymia, vertigo, dyspepsia, irritable bowel syndrome and premature ejaculation.
Physical properties about Levosulpiride are: (1)ACD/LogP: 0.776; (2)ACD/LogD (pH 5.5): -2.24; (3)ACD/LogD (pH 7.4): -1.08; (4)ACD/BCF (pH 5.5): 1.00; (5)ACD/BCF (pH 7.4): 1.00; (6)ACD/KOC (pH 5.5): 1.00; (7)ACD/KOC (pH 7.4): 1.00; (8)#H bond acceptors: 7; (9)#H bond donors: 3; (10)#Freely Rotating Bonds: 6; (11)Index of Refraction: 1.552; (12)Molar Refractivity: 88.183 cm3; (13)Molar Volume: 276.104 cm3; (14)Polarizability: 34.958 10-24cm3; (15)Surface Tension: 45.8950004577637 dyne/cm; (16)Density: 1.237 g/cm3
You can still convert the following datas into molecular structure:
(1)InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21);
(2)InChIKey=BGRJTUBHPOOWDU-UHFFFAOYSA-N;
(3)Smilesc1(c(ccc(c1)S(N)(=O)=O)OC)C(NC[C@@H]1[N@@](CCC1)CC)=O;
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intraperitoneal | 170mg/kg (170mg/kg) | European Journal of Medicinal Chemistry--Chimie Therapeutique. Vol. 17, Pg. 437, 1982. | |
mouse | LD50 | oral | 2450mg/kg (2450mg/kg) | Drugs of the Future. Vol. 12, Pg. 944, 1987. | |
rabbit | LD50 | intravenous | 42mg/kg (42mg/kg) | Drugs of the Future. Vol. 12, Pg. 944, 1987. | |
rabbit | LD50 | oral | > 1500mg/kg (1500mg/kg) | Drugs of the Future. Vol. 12, Pg. 944, 1987. | |
rat | LD50 | intraperitoneal | 270mg/kg (270mg/kg) | Drugs of the Future. Vol. 12, Pg. 944, 1987. | |
rat | LD50 | intravenous | 53mg/kg (53mg/kg) | Drugs of the Future. Vol. 12, Pg. 944, 1987. | |
rat | LD50 | oral | 2600mg/kg (2600mg/kg) | Drugs of the Future. Vol. 12, Pg. 944, 1987. |